// App-Quantinova.ai

e16550 : Intercalating docetaxel between novel hormone therapies (NHT) abiraterone and enzalutamide in metastatic castration resistant prostate cancer (mCRPC): Does it resensitize patients to the second NHT agent?

Researchers

Presenter

  • Benjamin Louis Maughan

Principal Investigators

  • Karim Boudadi

  • Rosa Maria Nadal

  • Emmanuel S. Antonarakis

Medical Centers

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • National Institute of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved